A Randomized Phase I-II Study of Fulvestrant vs Fulvestrant in Combination with Bortezomb in Women with ER Positive Metastatic Breast Cancer
ID Number 12-0039
Principal Investigator(s)Kerin Adelson
Department(s) or Division(s)
Hematology and Medical Oncology
Description
You may qualify for participation in this study because you have breast cancer that has spread outside of the breast and your cancer has progressed on hormone therapy.
Your cancer cells have a protein on the surface, called an estrogen receptor. The purpose of this study is to determine whether the combination of a drug called fulvestrant, which attaches to the estrogen receptor and blocks its activity, given in combination with a drug called bortezomib, that blocks the cancer cells ability to break down unwanted proteins, is more effective than fulvestrant alone. We have seen in the laboratory that when these drugs are given together, more breast cancer cells die than when either drug is given alone. If the combination works in people, it could slow down the spread of your cancer.
Contact Information
(212) 824-7308
(212) 824-7293
Recruiting Patients: Yes